---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000400"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:52:39.342404+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock reports FY2022 net loss of $134.5M; revenue up to $33.2M; apitegromab Phase 3 enrollment on track for 2023

## Summary
- Net loss of $134.5M ($2.26 per share) in FY2022; revenue $33.2M vs $18.8M prior year.
- Cash, cash equivalents, and marketable securities of $315M; expects to fund ops into 2025.
- Phase 3 SAPPHIRE trial enrollment of apitegromab on track to complete in 2023; top-line data expected 2024.
- 36-month extension data from Phase 2 TOPAZ trial expected in mid-2023; ~90% of patients remained on study.
- Appointed Tracey M. Sacco as Chief Commercial Officer in Feb 2023 to lead launch preparation for apitegromab.

## SEC filing metadata
- accession: 0001157523-23-000400
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000115752323000400/0001157523-23-000400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000115752323000400/a53357191.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000400
- JSON: https://secwatch.observer/filing/0001157523-23-000400.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000400.txt

## Key facts
- Earnings Releases
  Scholar Rock Holding Corp reported the full year ended December 31, 2022 results: revenue $33.2 million, net income net loss was $134.5 million, EPS $2.26 per share.
  - Period: the full year ended December 31, 2022
  - Revenue: $33.2 million
  - Net income: net loss was $134.5 million
  - EPS: $2.26 per share
  - Result: reported results
  source text: For the full year ended December 31, 2022, net loss was $134.5 million or $2.26 per share compared to a net loss of $131.8 million or $3.59 per share for the full year ended December 31, 2021. Revenue was $33.2 million for the year ended December 31, 2022, compared to $18.8 million for the year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1727196/000115752323000400/0001157523-23-000400-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.